Author

Michael D Miller

Merck - Cited by 15,594 - Virology - immunology - immunotherapy

Biography

Michael D Miller is currently working as a Professor. His/Her research interests. Michael D Miller is serving as an editorial member and reviewer of several international reputed journals. He/She has successfully completed his Administrative responsibilities.
Title
Cited by
Year
Raltegravir with optimized background therapy for resistant HIV-1 infection
RT Steigbigel, DA Cooper, PN Kumar, JE Eron, M Schechter, M Markowitz, ...New England Journal of Medicine 359 (4), 339-354, 2008200
880
2008
Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised …
JL Lennox, E DeJesus, A Lazzarin, RB Pollard, JVR Madruga, DS Berger, ...The Lancet 374 (9692), 796-806, 2009200
717
2009
Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection
DA Cooper, RT Steigbigel, JM Gatell, JK Rockstroh, C Katlama, P Yeni, ...New England Journal of Medicine 359 (4), 355-365, 2008200
592
2008
Rapid and durable antiretroviral effect of the HIV-1 integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of …
M Markowitz, BY Nguyen, E Gotuzzo, F Mendo, W Ratanasuwan, ...JAIDS Journal of Acquired Immune Deficiency Syndromes 46 (2), 125-133, 2007200
525
2007
Barriers to a cure for HIV: new ways to target and eradicate HIV-1 reservoirs
C Katlama, SG Deeks, B Autran, J Martinez-Picado, J Van Lunzen, ...The Lancet 381 (9883), 2109-2117, 2013201
354
2013
Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2 …
JJ Eron, B Young, DA Cooper, M Youle, E DeJesus, ...The Lancet 375 (9712), 396-407, 2010201
348
2010
Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naive HIV-1–infected patients: final 5-year results from …
JK Rockstroh, E DeJesus, JL Lennox, Y Yazdanpanah, MS Saag, H Wan, ...JAIDS Journal of Acquired Immune Deficiency Syndromes 63 (1), 77-85, 2013201
285
2013
Raltegravir versus efavirenz regimens in treatment-naive HIV-1–infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses
JL Lennox, E DeJesus, DS Berger, A Lazzarin, RB Pollard, JVR Madruga, ...Journal of acquired immune deficiency syndromes (1999) 55 (1), 39, 2010201
281
2010
Addition of a cholesterol group to an HIV-1 peptide fusion inhibitor dramatically increases its antiviral potency
P Ingallinella, E Bianchi, NA Ladwa, YJ Wang, R Hrin, M Veneziano, ...Proceedings of the National Academy of Sciences 106 (14), 5801-5806, 2009200
233
2009
Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial
JJ Eron, JK Rockstroh, J Reynes, J Andrade-Villanueva, ...The Lancet infectious diseases 11 (12), 907-915, 2011201
223
2011
Loss of raltegravir susceptibility by human immunodeficiency virus type 1 is conferred via multiple nonoverlapping genetic pathways
S Fransen, S Gupta, R Danovich, D Hazuda, M Miller, M Witmer, ...Journal of virology 83 (22), 11440-11446, 2009200
211
2009
PD-1 blockade in rhesus macaques: impact on chronic infection and prophylactic vaccination
AC Finnefrock, A Tang, F Li, DC Freed, M Feng, KS Cox, KJ Sykes, ...The Journal of Immunology 182 (2), 980-987, 2009200
158
2009
In Vitro Characterization of MK-1439, a Novel HIV-1 Nonnucleoside Reverse Transcriptase Inhibitor
MT Lai, M Feng, JP Falgueyret, P Tawa, M Witmer, D DiStefano, Y Li, ...Antimicrobial agents and chemotherapy 58 (3), 1652-1663, 2014201
118
2014
In Vitro Resistance Selection with Doravirine (MK-1439), a Novel Nonnucleoside Reverse Transcriptase Inhibitor with Distinct Mutation Development Pathways
M Feng, D Wang, JA Grobler, DJ Hazuda, MD Miller, MT LaiAntimicrobial agents and chemotherapy 59 (1), 590-598, 2015201
105
2015
Novel indole-3-sulfonamides as potent HIV non-nucleoside reverse transcriptase inhibitors (NNRTIs)
Z Zhao, SE Wolkenberg, M Lu, V Munshi, G Moyer, M Feng, AV Carella, ...Bioorganic & medicinal chemistry letters 18 (2), 554-559, 2008200
98
2008
Vaccination with peptide mimetics of the gp41 prehairpin fusion intermediate yields neutralizing antisera against HIV-1 isolates
E Bianchi, JG Joyce, MD Miller, AC Finnefrock, X Liang, M Finotto, ...Proceedings of the National Academy of Sciences 107 (23), 10655-10660, 2010201
73
2010
Potent and selective HIV-1 ribonuclease H inhibitors based on a 1-hydroxy-1, 8-naphthyridin-2 (1H)-one scaffold
PD Williams, DD Staas, S Venkatraman, HM Loughran, RD Ruzek, ...Bioorganic & medicinal chemistry letters 20 (22), 6754-6757, 2010201
68
2010
Raltegravir: the first HIV‐1 integrase strand transfer inhibitor in the HIV armamentarium
BYT Nguyen, RD Isaacs, H Teppler, RY Leavitt, P Sklar, M Iwamoto, ...Annals of the New York Academy of Sciences 1222 (1), 83-89, 2011201
65
2011
The A62V and S68G mutations in HIV-1 reverse transcriptase partially restore the replication defect associated with the K65R mutation
ES Svarovskaia, JY Feng, NA Margot, F Myrick, D Goodman, JK Ly, ...JAIDS Journal of Acquired Immune Deficiency Syndromes 48 (4), 428-436, 2008200
61
2008
Affinity maturation and characterization of a human monoclonal antibody against HIV-1 gp41
DL Montgomery, YJ Wang, R Hrin, M Luftig, B Su, MD Miller, F Wang, ...MAbs 1 (5), 462-474, 2009200
61
2009

Referred From: https://scholar.google.com/citations?user=i7OkugwAAAAJ&hl=en&oi=ao

Cited by
Citations 15594
h-index 60
i10-index 98
Recommended Journals
Open Access Journals